Niagen Bioscience Inc. (OCD1)
XMUN 
Summary
OCD1 Chart
ChromaDex Capitalizes On Longevity Boom But Valuation Remains High
ChromaDex Corporation shows strong revenue growth and profitability, driven by its NAD+ precursors and flagship product Niagen, despite high valuation and execution risks. Record-breaking financial performance includes a 37.41% revenue increase, $7.2 million net income, and expanded gross margins, with a significant e-commerce boost. The company faces challenges like supply chain issues, tariff risks, and regulatory uncertainties, which could impact its ambitious growth targets and market position.
ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript
ChromaDex Corporation (NASDAQ:CDXC ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financial Officer Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant Bill Dezellem - Tieton Capital Management Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital J.P.
ChromaDex (CDXC) Q4 Earnings and Revenues Surpass Estimates
ChromaDex (CDXC) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.
Niagen Bioscience Inc. (OCD1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Niagen Bioscience Inc. ever had a stock split?
Niagen Bioscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Frank Louis Jaksch Jr. CEO | XMUN Exchange | US1710774076 ISIN |
| US Country | 104 Employees | - Last Dividend | 13 Apr 2016 Last Split | 15 Jul 2008 IPO Date |
Overview
ChromaDex Corporation stands as a pioneering bioscience entity focused on the frontier of developing products aimed at promoting healthy aging. Since its inception in 1999, the company has been at the forefront of exploring the realms of nicotinamide adenine dinucleotide (NAD+), a critical molecule involved in the body's metabolic processes. With its headquarters nestled in Los Angeles, California, ChromaDex operates through a multifaceted business model that includes Consumer Products, Ingredients, and Analytical Reference Standards and Services. These diverse operations underline the company's commitment to leveraging science for enhancing human health and well-being, particularly in the context of aging.
Products and Services
ChromaDex Corporation's portfolio encompasses a wide array of offerings designed to support healthy living and aging. These products and services are distributed through various channels, including direct-to-consumer platforms, distributors, and healthcare practitioners, predominantly in the United States. The comprehensive suite includes:
- NIAGEN: A flagship ingredient commercialized by ChromaDex, NIAGEN is renowned for being a precursor to NAD+, playing a vital role in supporting cellular health and metabolism. Its incorporation into dietary supplements marks a groundbreaking advancement in the field of nutraceuticals.
- TRU NIAGEN Products: Under the brand name TRU NIAGEN, ChromaDex offers finished dietary supplement products that feature NIAGEN as the active ingredient. These products are aimed at boosting NAD+ levels in the body, thereby supporting various aspects of health and aging. TRU NIAGEN products are available to consumers through ChromaDex's proprietary e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as through specialty retailers and healthcare practitioners.
- Immulina: Another noteworthy offering is Immulina, a spirulina extract identified for its significant concentration of Braun-type lipoproteins. These compounds are instrumental in supporting human immune function, making Immulina a valuable addition to the company's lineup of immune-boosting products.
- Phytochemical Reference Standards and Research Services: Beyond consumer products, ChromaDex extends its expertise into the realm of scientific research and development. The company offers phytochemical reference standards, crucial for the accurate identification and quantification of plant-based compounds in various applications. Additionally, it provides a range of research and development services, catering to the needs of scientific investigation and product development across the bioscience industry.
Contact Information
